Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US5824318A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jul 24, 1996 |
| Grant date | Oct 20, 1998 |
| Priority date | — |
| Expiry date | Jul 24, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16634
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Isolated tumoricidal herpetic viruses, in particular neurotrophic herpes viruses, T-lymphotrophic viruses, and B-lymphotrophic viruses, which are avirulent and capable of selectively replicating in and destroying neoplastic cells, and pharmaceutical compositions, vaccines, and methods of destroying neoplastic cells employing the isolated tumoricidal herpetic viruses are described. A method of isolating tumoricidal herpetic viruses by sequentially passaging attenuated, avirulent herpetic viruses on neoplastic cells which fail to support replication of the herpetic viruses and isolating the viruses which grow on the neoplastic cells is also described. Herpes simplex virus mutants having a genome from which the .gamma.34.5 genes have been deleted and which require at least one additional mutation to produce a non-neurovirulent herpes simplex virus which selectively replicates in and destroys neoplastic cells are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.